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Abstract
The physiologically based pharmacokinetic (PBPK) models allow for predictive assessment of variability in population of
interest. One of the future application of PBPK modeling is in the field of precision dosing and personalized medicine. The
aim of the study was to develop PBPK model for amitriptyline given orally, predict the variability of cardiac concentrations
of amitriptyline and its main metabolite—nortriptyline in populations as well as individuals, and simulate the influence of
those xenobiotics in therapeutic and supratherapeutic concentrations on human electrophysiology. The cardiac effect with
regard to QT and RR interval lengths was assessed. The Emax model to describe the relationship between amitriptyline
concentration and heart rate (RR) length was proposed. The developed PBPK model was used to mimic 29 clinical trials
and 19 cases of amitriptyline intoxication. Three clinical trials and 18 cases were simulated with the use of PBPK-QSTS
approach, confirming lack of cardiotoxic effect of amitriptyline in therapeutic doses and the increase in heart rate along
with potential for arrhythmia development in case of amitriptyline overdose. The results of our study support the validity
and feasibility of the PBPK-QSTS modeling development for personalized medicine.
Keywords Pharmacokinetic/pharmacodynamic (PK/PD) modeling  Pharmacokinetics  Physiologically based
pharmacokinetic (PBPK) modeling  Toxicokinetics  Cardiac safety
Introduction
The physiologically based pharmacokinetic (PBPK) mod-
eling approach has been used for various applications such
as risk assessment for environmental health, academic
research or drug development purposes [1, 2], in short, the
safety and efficacy assessment. PBPK model parameters
describing anatomy and physiology of the chosen species
are compound-independent, which makes a model a uni-
versal framework for pharmacokinetics (PK) prediction in
tissues of interest [3]. What is more, if properly parame-
terized, mechanistic PBPK models can predict inter-indi-
vidual variability in drug’s PK profiles resulting from
differences in human anatomy and physiology. A priori
application of deterministic and/or stochastic approach in
description of covariates (PBPK model parameters)
affecting xenobiotics PK allows for predictive assessment
of variability in a population of interest [1]. The next,
future application of PBPK modeling that has already
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begun to be explored is in the field of precision dosing and
personalized medicine. A profile of certain individual can
be differentiated from a specific virtual population
according to age, sex, and other specific physiological
features [4, 5]. Such in silico models matching real
patients, so called ‘virtual twins’, were also proposed by
Polasek et al. [6] in order to predict individual olanzapine
exposures and adjust the therapeutic dose. Zurlinden et al.
[7] made use of that approach in the area of toxicokinetics,
i.e., to predict paracetamol time-concentration profiles in
humans under overdose condition, and to provide a method
for ingested dose estimation. Patel et al. [8] simulated
‘virtual twins’, taking into account real patients’ physiol-
ogy to mimic pharmacodynamics (PD), namely electro-
physiological effect of citalopram taken, both in
therapeutic and supratherapeutic doses.
Since, according to WHO, more than 300 million people
suffer from depression [9], a large population is exposed to
antidepressants. Although several new antidepressants
were introduced, the old generation of tricyclic antide-
pressants (TCAs) are still in use despite being well-known
for adverse cardiovascular effects [10]. Among TCAs,
amitriptyline (AT) has been recognized to be most com-
monly associated with QT interval prolongation, arrhyth-
mia, and the risk of sudden cardiac death [11]. The
correlation between severity of the clinical manifestations
of AT overdose and drug plasma levels is weak [12], so
other individual factors should be taken into account in the
attempts of prediction of drug adverse effects.
In this study we aimed to: (1) develop a PBPK model for
AT administered orally, (2) simulate variability in PK of
orally taken AT, and its main metabolite, nortriptyline
(NT), with the use of PBPK model, (3) compare predic-
tions versus clinically observed concentrations in differ-
ently characterized populations, (4) assess the ability of
developed PBPK model extrapolation to simulate PK of
overdosed real individuals, (5) estimate individual active
cardiac concentrations of AT and NT, and their variability
in the population, (6) simulate the effect of AT, and its
main metabolite, NT, on human electrophysiology, both,
observed clinically in populations and in overdosed
patients (QSTS—Quantitative Systems Toxicology and
Safety [13]) with the use of drug cardiac concentrations
predicted in PBPK model.
Methods
The workflow of the study and the exploitation of collected
data is presented in Fig. 1.
PBPK model structure
We used full-PBPK model developed for AT linked to
minimal-PBPK model for the metabolite—NT [14] without
changing any of the model parameters. The model had
been built for intravenous AT administration and accoun-
ted for inter-individual variability. In order to implement
the oral route of AT administration into the model, the drug
absorption process was described with the equation of first
order kinetics (Eq. 1):
dDoseF
dt
¼ ka  DosePO  F ð1Þ
where dDoseF
dt
mg
h
 
is the rate of taken orally AT entering the
venous compartment, ka [h
-1] is the first order absorption
rate, DosePO [mg] is the oral dose (po) of AT counted as a
free base, and F is the AT bioavailability. Assuming:
F ¼ ðfa  FgÞ  Fh ð2Þ
where fa is the fraction of administered dose of AT
absorbed to enterocytes, Fg is the fraction of AT escaping
gut wall metabolism and entering portal vein, and Fh is a
fraction of AT escaping liver metabolism during the first
pass, the process of NT formation in the liver compartment
in the first-pass metabolism was described as (Eq. 3):
dANT
dt
¼ MWNT
MWAT
 ð1  Fðfa  FgÞ
Þ  ðfa  FgÞ  DosePO
ð3Þ
where dANT
dt
mg
h
 
is the rate of NT formation in the liver
compartment in the first-pass metabolism, MWNT [g/mol] is
NT molecular weight, and MWAT [g/mol] is AT molecular
weight. AT absorption and NT formation were assumed to
occur with mean lag time tlag [h] with 30% CV. In case of
multiple-dosage regimens patient-specific tlag was assumed
to be constant in time.
The values for the parameters describing AT absorption
process were as follows:
ka—estimated in the optimization process, DosePO—
study-dependent, F—drawn from normal distribution of
mean 0.459, standard deviation 0.093, truncated at 0.33 and
0.62 [15], (fa9 Fg)—drawn from log-normal distribution
of mean 0.832 and coefficient of variation 0.131 [16],
MWNT equals 263.384 g/mol [17], MWAT equals
277.4 g/mol [18], and tlag—estimated in the optimization
process.
Two of the parameters of the absorption model, i.e., ka
and tlag were fitted to the mean concentrations of AT and
NT in plasma observed in three clinical studies after oral
administration of AT [19–21]. These studies were chosen
based on the criteria such as: representation of different
doses of AT, mean plasma concentration reported both for
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AT and NT, inclusion of the Caucasian population (if not
indicated directly, at least probable according to the
authors affiliation). If two or more clinical studies char-
acterized by the same dose of AT administered were ful-
filling the criteria, the study with the PK reported for the
longer period of time was chosen for fitting purposes.
The start values (intervals) set for both optimized
parameters in the fitting process were set to 1 [0.1–2], and 1
[0–2] for ka and tlag, respectively. The model cost was
estimated as the root-mean-square error weighted by time
(W-RMSE). Fitting was performed using the R statistical
environment (version 3.4.1) with nloptr module used for
global optimization and L-BFGS-B method of optim()
procedure for local optimization. In the global optimization
method controlled random search algorithm with local
mutation (CRS2) was applied [22]. CRS2 is a global
optimization method with constraints based on genetic
algorithm coupled with random Nelder-Mead search
strategy. After the CRS2 run with predefined number of
iterations set to 1500 its solution was passed further to the
L-BFGS-B method for refinement and final values of ka
and tlag were obtained. The L-BFGS-B [23] method is a
variation of classical quasi-Newton approach delivered by
Broyden, Fletcher, Goldfarb and Shanno [24, 25]. This
algorithm is capable of constrained optimization and
therefore provides physically acceptable results of ka and
tlag The number of L-BGFS-B iterations was set to 50 and
relative tolerance stop criterion was set to 1e-20. For both
approaches the internal optimization cost function was
W-MSE (weighted mean squared error), transformed after
the optimization into the W-RMSE for clarity of interpre-
tation. The optimization runs were performed under Linux
environment with R batch mode execution of R scripts.
Pharmacodynamic models
The ten Tusscher ventricular cardiomyocyte cell model
[26] implemented in the Cardiac Safety Simulator (CSS) v.
2.1 (Simcyp, Sheffield, UK, a Certara company) [27] was
used to simulate pseudo-ECG traces. The CSS platform
allowed for integration of the individual cardiac concen-
trations simulated in PBPK model, patient-specific infor-
mation, and in vitro measured ion channels inhibition and
consequent translation to in vivo human situation.
It is a known fact, that AT can modify the heart rate
[28], therefore to describe the relationship between AT
concentration and R–R interval length, an Emax model was
established (Eq 4):
RR ¼ ðRR0  RRmaxÞ  C
n
ECn50 þ Cn
ð4Þ
Were RR is the R–R interval length [ms], RR0 is the
baseline R–R interval length [ms], RRmax is the maximum
R–R interval length [ms], EC50 is the AT concentration that
produces 50% of RRmax, C is AT total plasma concentra-
tion [lM], and n is the sigmoidicity factor. The Emax model
was fitted to literature-derived data [29–46] in R v. 3.4.0.
with the use of simulated annealing ‘‘SANN’’ method of
optimization from FME package [47].
Fig. 1 a The workflow of the study. The consecutive steps are listed
in the blocks from top to bottom. The respective software was written
in square brackets. b The exploitation of collected data for model
optimization, PBPK model performance verification, and PBPK-
QSTS modeling purposes
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Model performance: therapeutic doses
in populations
PBPK model performance verification was conducted by
simulating clinical studies described in the literature where
AT in therapeutic doses was administered orally. Simula-
tions were run starting from the seed set to 1111. The
results were compared with experimentally observed data,
which were manually digitized from the published plots.
The assessment of the model performance was based on:
1. visual inspection,
2. calculated ratios of the mean of predicted concentra-
tions to mean of observed concentrations,
3. calculated ratios of predicted AUC to observed AUC.
Scientific literature resources were searched with the
combinations of ‘‘amitriptyline’’, ‘‘pharmacokinetics’’,
‘‘clinical trial’’, ‘‘QT’’ within PubMed/Medline and
GoogleScholar. Twenty-four papers reporting PK of either
AT alone or together with its metabolite, NT, after oral
administration of AT in standard-release forms were
identified. The populations described in the publications in
question were either healthy or depressed with no other
comorbidities. All of the identified studies were mimicked
in modeling and simulation experiment. Three of them
[19–21] served the purpose of parameters optimization.
The other three [36, 48, 49], which contained data on time-
matching QT measurement, entered the PK/PD modeling
part of the study. The details of simulation scenarios are
presented in Table 1 in Supplementary Material.
The simulated free AT and NT cardiac concentrations
served as input values in CSS. The observed QTc values
with time-matching QTc derived from simulated pseudo-
ECG traces were compared. In QT length correction
methods for heart rate we followed those described in
clinical trials as close as possible.
Model performance: clinical cases of AT
intoxication
The established and verified PBPK model for oral admin-
istration of AT was used to predict individual toxicokinetic
profiles (toxPK) of AT and NT in plasma and the heart
tissue in case of AT overdose, and its impact on human
electrophysiology. Scientific literature resources were
searched with the combinations of ‘‘amitriptyline’’,
‘‘overdose’’, ‘‘intoxication’’, ‘‘QT’’, ‘‘TdP’’ within
PubMed/Medline and GoogleScholar. Nineteen clinical
cases of AT intoxication, in which there were no known
other drugs altering cardiac electrophysiology taken, esti-
mated dose and/or at least parent compound plasma con-
centration were reported, and time-matching QT (or QTc)
measurement was available along with patient
characteristics.
The found cases were divided into three groups with
corresponding methodology:
1. Cases without ingested dose reported [35, 43]: the free
cardiac AT and NT concentrations were estimated
based on observed plasma AT and NT concentrations
according to the (Eq. 5):
Cfree;cardiac ¼ Ctotal;plasma Kpht  fuht ð5Þ
where Cfree,cardiac is drug free cardiac concentration,
Kpht is heart tissue to plasma partition coefficient, and
fuht is drug unbound fraction in heart tissue. For AT,
Kpht = 11.77, and fuht = 0.0012. For NT, Kpht-
= 35.63, fuht = 0.001. If plasma NT concentrations
was unavailable, it was assumed to equal half of the
observed AT plasma level.
2. Cases with both the estimated dose, and drug plasma
concentrations reported [34]: ToxPK profiles were
simulated in PBPK model and compared with observed
plasma concentrations. The simulated free cardiac AT
and NT concentrations were input into CSS for PD
modeling. Since only the postdose time interval of
ECG measurement was available, the cardiac concen-
trations corresponding to the simulated maximal
plasma concentration of AT in that time interval were
used.
3. Cases without drug plasma concentrations reported
[12, 50–52]: The free cardiac concentrations of AT and
NT were predicted in PBPK model based on the
estimated toxic dose, and used as input in CSS.
All toxPK simulations were run ten times with the initial
seed set to 1111. If the subject described in the clinical
study claimed to take AT before the incident or suffer from
depression, the toxic dose ingestion was simulated after the
concentration reached steady-state. The data on individu-
als’ potassium, sodium, and calcium plasma levels, and RR
interval length were taken into account if available in
simulation of AT-triggered cardiac effect in CSS. In the
case of no information on ions concentrations, they were
assumed to be normal and the default settings in CSS were
kept. In one case, i.e., the case reported by Paksu et al. [12],
the RR was not available. Therefore in that case, the
individual values of RR were predicted in Emax model
based on simulated AT concentrations. The mean value of
model derived RRs was input in CSS in Paksu study
simulations.
The outputs of CSS were compared with the endpoints
reported in case studies. It included: QT, QTcB, or torsade
de pointes (TdP) arrhythmia event.
The details of simulation scenarios are presented in
Table 1 in Supplementary Material.
666 Journal of Pharmacokinetics and Pharmacodynamics (2018) 45:663–677
123
Results
Estimates of the parameters
The W-RMSE estimated for initial values of optimized
parameters was 10.01 and decreased to 9.24 after running
the model-fitting algorithms. All computations were run on
a multiserver, multicore grid, working under the control of
job control system. Despite that, there was no significant
reduction of fitting, thus we conclude that the model is
stable and its parameters represent the closest possible
estimates of the final values. The estimates were as fol-
lows: ka= 0.24 [h
-1] and tlag= 1.33 [h].
Emax model
The estimates of Emax model parameters were as follows:
RR0 = 995.3 [ms], RRmax = 500.8 [ms], EC50 = 0.4
[lM], and n = 1.5. The RMSE of established Emax model
equaled 120.98. The RR interval length versus AT plasma
concentration simulated in Emax model is depicted in Fig. 2
along with the values clinically observed.
Model performance: therapeutic doses
in populations
With the use of PBPK model, 29 trials in which AT was
administered orally either as a single dose (20 studies) or in
multiple dosage schedules (9 studies), were mimicked.
Regarding single AT dose administration, the PK after
following doses was simulated: 10 mg [53], 25 mg
[19, 53–56], 40 mg [57], 50 mg [20, 58–63], 75 mg
[21, 48, 64], 80 mg [57], and 100 mg [59]. The simulated
PK profiles along with AT and NT (if available) concen-
trations observed in the clinic are presented in Fig. 1 A-AC
in Supplementary Material. The predicted mean
concentrations of AT were within two-fold of their
respective observed means for 18 (out of 20) studies
(Fig. 3).
The simulated AUC of AT were within two-fold of their
respective AUC derived from clinically observed data for
12 (out of 15 for which the AUC value was reported)
studies (Fig. 4).
The simulated Cmax for AT were within two-fold of their
respective clinically observed Cmax for 9 (out of 11 for
which the Cmax value was reported) (Fig. 4). The predicted
mean concentrations of NT were within two-fold of their
respective observed means for 8 (out of 15) studies
(Fig. 3). The simulated AUC of NT were within two-fold
of their respective AUC derived from clinically observed
data for 5 (out of 9 for which the AUC value was reported)
studies (Fig. 4).
Regarding multiple AT dose administration, the PK
after the following dosage schemes was simulated: 25 mg
q.d. [21], 25 mg t.i.d. [65], 50 mg t.i.d. [65], 75 mg q.d.
[66, 67], 125 mg q.d. [68], AT in ascending doses, i.e.,
100 mg–150 mg–200 mg q.d. [49], 75 mg–150 mg
[36, 69]. The predicted mean concentrations of AT were
within two-fold of their respective observed means for 7
(out of 9) studies. The predicted mean concentrations of
NT were within two-fold of their respective observed
means for 6 (out of 9) studies (Fig. 3).
Free AT and NT cardiac concentrations simulated under
the scenarios of three clinical trials [36, 48, 49] were fur-
ther used as input values in CSS to mimic the electro-
physiological effect of administered drug measured in
those clinical trials.
The effect was expressed as DQTc—the difference
between QT interval length after drug administration and
baseline QT interval length measured in a situation without
a drug. The results of PBPK-QSTS modeling compared to
observed values are presented in Fig. 5.
In the study by Pickup et al. [48] the mean simulation
results of DQTc were from - 1.07 ms (1 h postdose) to
2.90 ms (6 h postdose) versus DQTc clinically observed
from - 14.4 ms (2 h postdose) to - 1.94 ms (6 h post-
dose). In the study by Warrington et al. [36] the mean
simulation results of DQTc were - 4.25 ms (in the 12th
day of treatment) and - 1.05 ms (in the 14th day of
treatment) versus DQTc clinically observed: 0 ms (in the
12th day of treatment) and - 5 ms (in the 14th day of
treatment). In the study by Upward et al. [49] the mean
simulation results of DQTc were - 7.75 ms (in the 1st
week of treatment) and - 6.62 ms (in the 4th week of
treatment) versus DQTc clinically observed: - 7 ms (in the
1st week of treatment) and 6 ms (in the 4th week of
treatment).
400
600
800
1000
0 5 10 15
Plasma AT Concentration [μM]
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female
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not available
RR ~ AT Concentration, Emax model
Fig. 2 The Emax model total plasma AT concentration [lM] - RR
interval length [ms] curve along with the values clinically observed
(dots)
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Model performance: clinical cases of AT
intoxication
The PK in 19 cases of AT intoxication was simulated. The
simulations’ results are presented as time-concentration
profiles of AT and NT in plasma, and in cardiac tissue in
Fig. 2 A–P in Supplementary Material. Because of lack of
clinically observed precise data on time-matched
concentrations of AT and NT, presentation of other PK
metrics on the goodness of model prediction was not
possible. The results of the cases are described in the order
defined in the Materials and Methods section:
1. The predicted mean QTcB in the study mimicking that
described by Zakynthinos et al. [43] was 531 ms
(520 ms observed in the clinic). In one out of ten
Case Study
Multiple Dose
Single Dose
1 2 3 4
Schulz (elderly man) [57]
Schulz (young man) [57]
Baumann [69]
Gupta (multiple dose) [21]
Gupta [66]
Miljkovic (3 x 25 mg) [65]
Miljkovic (3 x 50 mg) [65]
Minton [67]
Upward [49]
Vandel [68]
Warrington [36]
Balant−Gorgia [64]
Bhatt [58]
Burch (100 mg) [59]
Burch (50 mg) [59]
Curry [19]
Dorian [54]
Ghahramani [60]
Gupta (single dose) [21]
Jang [61]
Liedholm [55]
Mellstrom [62]
Nam (10 mg) [53]
Nam (25 mg) [53]
Ogura (elderly men) [56]
Ogura (young men) [56]
Pickup [48]
Venkatakrishnan [20]
Warrington [63]
Ratio
S
tu
dy
Drug
amitriptyline
nortriptyline
Fig. 3 The ratio of predicted
mean concentrations to
observed mean concentrations
of AT (red dots) and NT (blue
dots). Two-fold margin is
marked in pink (Color figure
online)
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simulated patients, arrhythmia was observed. The
predicted mean QTcB in the study mimicking that
described by Schmidt et al. [35] was 480 ms (517 ms
observed in clinic).
2. The predicted QT interval length for AT overdose
described by Rudorfer [34] were in the range of
330–373 ms (observed range: 316–438 ms). In eight
simulations, 1–2 virtual patients developed arrhythmia
Balant −Gorgia [64]
Bhatt [58]
Burch (100 mg) [59]
Burch (50 mg) [59]
Curry [19]
Dorian [54]
Gupta (single dose) [21]
Jang [61]
Liedholm [55]
Nam (10 mg) [53]
Nam (25 mg) [53]
Ogura (elderly men) [56]
Ogura (young men) [56]
Venkatakrishnan [20]
Warrington [63]
0 1 2 3
Ratio
S
tu
dy
Drug
amitriptyline AUC
amitriptyline Cmax
nortriptyline AUC
Fig. 4 The ratio of predicted to
observed dose metrics: AUC for
time-concentration profile of
AT (red dots), AUC for time-
concentration profile of NT
(blue dots), Cmax for AT (green
dots). Two-fold margin is
marked in pink (Color figure
online)
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(in clinics the arrhythmia on admission was reported in
6 cases).
3. The predicted mean QT in the study mimicking that
described by Erdem et al. [50] was 355 ms (400 ms
observed). The predicted mean QTcB in the study
mimicking that described by Kiyan et al. [51] was
505 ms (521 ms observed in the clinic). The predicted
mean QTcB in the study mimicking that described by
Paksu et al. [12] was 512 ms (488 ms observed in the
clinic). In case of a virtual 25-year-old female with
TdP described by Abeyaratne et al. [52], the arrhyth-
mia was simulated in two out of ten virtual patients.
The simulated QT or QTc for each of the clinical cases
along with clinical observations are shown in Fig. 3 A–R in
Supplementary Material. An exemplary simulation results
of individual time-concentration profiles and QT of a
67-year old female intoxicated with 2500 mg of AT are
presented in Fig. 6. The mean predicted QT or QTc values
from all clinical cases are shown in Fig. 7.
Discussion
The literature-derived data suggest that there is substantial
variability in AT and its metabolite PK observed in the
population. It is also the case for the electrophysiological
effect of AT, especially in the situation of drug poisoning.
We aimed to predict the variability in PK/PD of AT with
the use of modeling and simulation paradigm in terms of
both, population analysis, and individual cases.
Modeling the absorption of AT
The basis of the developed system consisted of the recently
developed PBPK model for AT and NT established for AT
administered intravenously [14]. To keep the model as
mechanistic as possible, any of the already established
parameters was changed, and the model was extrapolated
to the oral route of drug administration. Intestinal absorp-
tion is a complex process affected by many drug- and
physiology-related factors [70, 71]. The systemically
available fraction of an administered dose is the result of
the processes occurring in the guts (e.g., metabolism,
influx, efflux) and the fraction escaping hepatic first-pass
extraction [72]. Mechanistic modeling of gastrointestinal
absorption and bioavailability usually requires further
segmentation of gastrointestinal track compartment along
with its rich parametrization [70, 71, 73, 74]. Our model
was developed based on the heterogeneous data derived
from various sources, lacking precise information on AT
formulation. AT absorption was characterized empirically,
assuming first order absorption process. The average values
Pickup [48] Warrington [36] Upward [49]
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Fig. 5 The results of PBPK-
QSTS modeling in CSS in ten
Tusscher and Panfilov [26]
ventricular cardiomyocyte cell
model (in blue) compared to
clinically observed values (in
red) of three clinical trials
[36, 48, 49]. The results are
presented as mean with standard
deviation of DQTc (Color figure
online)
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and their distributions of (fa 9 FG) and F for AT were
based on observations in humans [15, 16]. (fa9 Fg) was
drawn from log-normal distribution of mean 0.832 and
coefficient of variation 0.131 [16] without truncation, so
the randomly assigned values can reach values larger than
1. It is justified by the enterohepatic circulation that AT is
said to undergo [75, 76]. The estimated ka equal 0.24 [h
-1]
and mean tlag equal 1.33 [h] (assuming CV = 30%) suggest
the AT absorption process to be rather slow and delayed in
relation to the time of drug ingestion. Although this
empirical approach does not give an insight into the
physiological aspects of AT absorption, it reflects the net
underlying contribution of solubility and dissolution pro-
cesses, that drug molecules undergo, time of gastric emp-
tying and intestinal transit [72, 77]. Since the parameters
were fitted to three trials characterized by different AT
doses and different populations, it seemed justified to
extrapolate the estimates in further simulations, for the
remaining studies.
Variability in PK of AT in different populations
The PBPK model was capable of providing estimates of the
average concentration, the AUC, and the Cmax within two-
fold in most of the simulated trials in terms of both, AT,
and its metabolite—NT. The visual inspection (Fig. 1
Supplementary Material) and the dose metrics (Figs. 3, 4)
reveal that the model underpredicts the metabolite, i.e., NT
concentration. This limitation may be partly explained by
the use of simple, minimum-PBPK model to capture PK of
the metabolite and not taking into account the NT that is
formed during the intestinal metabolic transformation of
AT. It is worth noting that none of the model parameters of
the previously established model was changed. Because of
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Fig. 6 The exemplary
individual results of PBPK and
PBPK-QSTS modeling in case
of 67-year old female
intoxicated with 2500 mg of AT
[34]. a The 1st column contains
profiles of AT concentrations,
the 2nd has NT concentrations.
The 1st row has drug
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online)
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the scarce data on NT concentration after AT infusion, the
model had been fitted to the data derived from only one
individual [57]. The model extrapolation to the oral
administration of AT in the same individual and another
one described in the same source publication was satisfying
as the ratio of dose metric met the criterion of two-fold
error; it equaled 0.75, and 0.94, respectively (Fig. 3).
Probably the estimate of KpreNT (the tissue to plasma
partition coefficient for NT for remaining tissues in the
body that were lumped into the ‘rest’ compartment in the
minimal PBPK model), although suiting those two cases,
does not reflect the average partition coefficient for the
population. It can be understandable since the Kps values
of NT for different tissues derived from human postmortem
data have very wide ranges, for example for the brain the
Kp is observed to be in between 5.0 [78] and 37.0 [79], or
for the liver from 5.2 [79] to 160.0 [80].
The simulated clinical studies comprised the AT doses
in the range from 10 to 100 mg. Besides the margin doses,
the PK profiles after other doses were simulated under the
scenarios of different populations. The experimentally
measured concentrations show a substantial variability in
PK after the same doses. For example Cmax observed after
50 mg of AT given orally varied from 16.7 ng/mL [63] to
50.7 ng/mL [61], which is a three-fold difference. The
study by Fagiolino et al. [81] was excluded from the
analysis. Although it met the criteria set out in Materials
and methods section, it provides the data one order of
magnitude higher than in other studies (Cmax at 606 ng/
mL) and a systematic error may be suspected. We were not
able to mimic in our model the PK at the lower extreme of
observed dose metric: the AUC, Cmax, and the average
concentration was overpredicted more than three times in
case of the Warrington study [63]. At the upper extreme of
observed dose metric there was a study by Jang et al. [61]
which was most probably conducted in a Korean popula-
tion, assuming that the authors affiliation reflects the origin
of the subjects taking part in the study. Although our model
was parameterized in such a way as to reflect the variability
in Caucasian population, its extrapolation to the Asian
population appeared to be good enough to capture the AT
PKs profiles within two-fold of their respective metrics
[53, 56, 61]. Another source of variability in PK comes
from polymorphism in the enzymes engaged in the drug
metabolism [82, 83]. In most of the mimicked studies the
participants did not have the CYPs phenotype assessed
with exception of two trials [20, 64]. In Venkatakrishnan’s
[20] study only one subject was determined as CYP2D6
poor metabolizer. The others were CYP2D6 and CYP2C19
extensive metabolizers. In the trial carried out by Balant-
Gorgia et al. [64] the ratio of number of poor hydroxylators
to extensive hydroxylators was 3: 4. Although our PBPK
model does not allow for CYPs phenotype determination,
the prediction of AT PK profile met the criteria of being
within two-fold error ranges. However, the NT PK profile
was underpredicted over 2.5 times. Being aware of the
model’s limitations it can be concluded that its predictions
are good enough to make use of the model’s capability of
predicting free drug cardiac concentrations which is sug-
gested to trigger cardiac effect [84]. The PBPK model
performance verification was done for single as well as
multiple therapeutic doses of AT in different populations.
PBPK: QSTS at the population level
AT has been on the market for more than 50 years and is
still frequently prescribed [85]. However, there is QT
interval prolongation listed among its side effects and
according to CredibleMeds [86] it is classified as ‘‘drug with
conditional TdP risk’’. The conditions that predispose sub-
ject to drug-related TdP are as follows: bradycardia, low
serum potassium or magnesium level, excessive dose,
impaired drug elimination, and drug PD interaction. The
main AT metabolite—NT—has been assigned to category
of ‘‘drugs with possible TdP risk’’. According to the ICH
E14 guidance [87] on drug cardiac safety, the evaluated
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Fig. 7 The results of PBPK-QSTS modeling in CSS in ten Tusscher
and Panfilov [26] ventricular cardiomyocyte cell model (in blue)
compared to clinically observed values (in red). The results are
presented as mean with standard deviation of QT or QTcB (Color
figure online)
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endpoint that the regulators are concerned about is QT/QTc
prolongation exceeding 5 ms, as judged by whether the
upper bound of the 95% confidence interval around the
mean effect on QTc exceeds 10 ms. Under the normal
conditions and in therapeutic doses, AT should not put one
at risk of TdP arrhythmia and the clinical trials on AT
confirm the AT cardiac safety. We have confirmed that
observations in numerical experiment with the in silico
realised PBPK-QSTS model. The use of the predicted free
cardiac AT and NT concentrations as input in ten Tusscher
[26] model implemented in CSS allowed for confirmation
of no effect of AT used in therapeutic doses on QT/QTc in
either healthy individuals or at least with no physical illness.
The model turned out to be capable of predicting AT car-
diac safety under different scenarios (single/multiple dose)
and in different time scales: hourly -, daily-, and weekly
time scale. The simulated mean DQTc did not exceed 5 ms
in neither of the assessed time points, likewise in the clinical
trials. There was only one exceptional observation, i.e., the
difference between mean QTc measured in the 4th week of
AT treatment and the mean QTc at baseline equaled 6 ms in
the study by Upward et al. [49]. However, since that trial
was conducted in the 1980’s, it was not designed according
to the current ICH E14 guidelines and the results allowed
the authors for the conclusion that ‘‘the QTc was not sig-
nificantly altered’’. When discussing the results the authors
pointed out the AT-related increase in heart rate, which was
not taken into account in case of therapeutic concentrations,
which may cause the difference between the simulation and
the observation in that time point for this particular study.
When following the study by Pickup et al. [48], in which the
information on precise time of the day of ECG assessment
was provided, in CSS simulation we considered not only
inter-individual- but also intra-individual variability which
results from circadian rhythms in heart rate and ion con-
centrations [88, 89]. Thus, the trends in DQTc values
observed by Pickup et al. were confirmed: the higher DQTc
occurred in the afternoon with the highest value observed
(and simulated as well) 6 h postdose. The only difference
was for the trend of the DQTc values in 1 and 2 h postdose.
PBPK: QSTS model applied to individuals
We went a step further from population PBPK-QSTS
analysis towards so called ‘personalized medicine’ and
simulation of drug adverse reactions in ‘virtual twins’ [8]
based on the established PBPK model structure [14] and
ventricular cardiomyocyte cell model [26], both accounting
for inter-individual variability. Although personalized
therapy was not the aim of the study, the developed PBPK
model has a capability of being used for this purpose.
Modeling the individual cases of AT intoxication proving
the model to be functional, should be viewed as the first
step in personalizing the treatment via modeling and sim-
ulation approach, Since very detailed data on patient’s
characteristic were lacking, we stuck to the patient’s age,
sex, previous AT treatment, heart rate, potassium, sodium,
and calcium concentrations, if available. Due to the specific
character of simulated cases, i.e., AT intoxications, the
ingested dose and time of AT ingestion were estimated
approximately by the clinicians, and the measurements of
drugs concentrations were provided only in one time point.
Therefore, the assessment of goodness of model prediction
other than visual inspection was not possible. The extrap-
olation of our PBPK model to toxic doses was preceded by
the model verification in case of therapeutic ranges of AT
levels. Only those studies in which most probably no other
drugs besides AT were taken by the patients were chosen.
The only one exception was the case described by Schmidt
et al. [35], where along with AT, tilidine, lorazepam, and
ethanol were known to be taken. However neither of these
substances is on the CredibleMeds list [86], so no PD
interaction was assumed, and measured instead of the
simulated AT and NT concentrations were used directly to
calculate free cardiac concentration (1st group of cases
described in the Materials and Methods section).
Regarding the 2nd group of cases described in the
Materials and Methods section, the PBPK model predic-
tions matched or were very close to the measured con-
centrations (Supplementary Material Fig. 2) despite the
inaccurate clinical data, which confirmed PBPK the mod-
el’s feasibility. Free cardiac concentrations used as the
driving force for the simulation of the pseudo-ECG traces
gave good results, as judged by comparison of means of
predicted and observed QT or QTcB length (Fig. 5). In
most cases, the overdosed patients suffered from tachy-
cardia, so Bazett correction of QT interval length for heart
rate was unjustified [90]. It was used only if such an ECG
parameter was provided in the source paper.
It seems that AT in supratherapeutic doses more fre-
quently poses an effect on the heart rate rather than on QT
interval length [28, 34]. That observation led to the Emax
model development which binds the RR interval length
with AT plasma concentration. The Emax model was used
when mimicking the case study reported by Paksu et al.
[12]—case no. 26 in the source publication, for which the
total estimated dose (750 mg) was provided. The observed
QTc length (488 ms) were in between the minimal
(481.6 ms) and maximal (533.7 ms) value of QTc simu-
lated for that case (Supplementary Material, Fig. 3O). It
showed that Emax model worked in practice. It is worth
adding that in some cases [12, 34] the arrhythmia was
reported. In our simulations often one to two out of ten
virtual patients poisoned with AT developed arrhythmia.
Since all of ten simulations, for each of the mimicked
cases, were run with the same settings regarding AT and
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NT concentrations and heart rate, there were other patient
specific parameters that mattered and predisposed the vir-
tual individuals to electrophysiology disruptions. Indeed,
the severity of clinical findings of AT intoxication is
weakly correlated with AT serum levels [12]. Abeyaratne
et al. [52] described the case of 25-year old female intox-
icated with ca. 500 mg of AT who developed TdP
arrhythmia 2 h after poisoning. 500 mg is much smaller
dose than in other reports, for example 3000 mg [34] or
almost 4000 mg [50] which were not associated in those
specific cases with arrhythmia occurrence. In Abeyaratne’s
study simulation the TdP in 2 out of 10 virtual individuals
was repeated. The feature that distinguished that case from
the others is the fastest heart rhythm (165 bpm). The ion
concentrations of the patient were unknown and assumed
to be normal. Detailed knowledge of patient’s biochemical
parameters should improve the PD predictivity.
There are other cases of AT-related TdP described in the
literature which were not simulated because of either
lacking information on AT dose or concentration [91],
pediatric case [92] or co-medication (fluconazole [93],
loperamide [94]) that may pose an effect on cardiac elec-
trophysiology. Because those cases are the examples of
arrhythmia not only related to TCA overdose, they support
the thesis that the drug triggered cardiotoxicity is a com-
plex process, and many internal, as well as external factors,
should be taken into account in model-based drug safety
assessment. It seems justified to state that verified PBPK-
QSTS models can be of help for the population and indi-
viduals safety assessment.
Conclusions
The herein described PBPK model allows for AT and NT
free cardiac concentration predictions. The model was
verified in terms of PK and the usefulness of predicted
cardiac concentrations for AT-related electrophysiology
effect modeling as well. Detailed mechanistic models
which have the ability to predict between-subject vari-
ability have the potential of PK or PK/PD assessment in
population, as well as in certain individuals providing that
patient-specific information is available. The results of our
study support the validity and feasibility of the PBPK-
QSTS modeling development for personalized medicine.
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